PREVENT Replaced the Old Cholesterol Risk Score: What Your Number Means Now

If you have ever had a clinician quote a 10-year risk number for heart attack or stroke, that number was almost certainly produced by an equation called the Pooled Cohort Equations (PCE). The PCE shaped statin decisions, blood pressure targets, and "you should think about this" conversations across U.S. cardiology for over a decade.

In March 2026, the PCE was retired.

The American College of Cardiology, American Heart Association, and nine partner societies released the 2026 Guideline on the Management of Dyslipidemia on March 13, 2026 — the first major U.S. cholesterol guideline update since 2018. Its biggest change is what the guideline recommends as the primary risk calculator for primary prevention. The new equation is called PREVENT-ASCVD, and it does several things the old PCE could not.

Here is what changed, what your number means now, and how the inputs that move it map to habits you can actually track.

Why the Pooled Cohort Equations Were Retired

The PCE were derived from cohort data assembled in the 1990s and early 2000s. They estimated 10-year risk of a first hard atherosclerotic cardiovascular disease (ASCVD) event — a heart attack, stroke, or death from those causes. They were the standard for over a decade and were the basis for the well-known 7.5% risk threshold often used in statin decisions.

Two problems accumulated over time.

First, validation studies in more recent cohorts showed the PCE consistently overestimated risk. The ACC's press release on the new guideline notes that the PCE "overestimated the 10-year risk of a heart attack and stroke by 40% to 50%." That is a large enough miscalibration to materially change statin recommendations for millions of adults.

Second, the PCE only produced a 10-year number. For a 35-year-old, a 10-year ASCVD risk is almost always low — but that does not mean a 35-year-old with high LDL cholesterol and a family history of early heart disease has nothing to act on. The 10-year window obscures lifetime risk.

PREVENT-ASCVD was designed to fix both problems.

What PREVENT Is and What It Does Differently

PREVENT stands for Predicting Risk of cardiovascular disease EVENTs. The equations were developed by the AHA's Cardiovascular-Kidney-Metabolic Science Advisory Group and published in Circulation in late 2023 (Khan et al.). They were derived from contemporary cohorts including the Atherosclerosis Risk in Communities (ARIC) study, the Multi-Ethnic Study of Atherosclerosis (MESA), and several others, with a much more diverse and modern population than the cohorts behind the PCE.

The 2026 guideline formally adopts PREVENT-ASCVD for primary prevention. Three things distinguish it from the PCE.

1. It Produces Both 10-Year and 30-Year Risk Estimates

This is the change that matters most for younger adults. PREVENT generates a 10-year number, the same window the PCE used, but it also generates a 30-year projection. For someone in their thirties or forties, the 30-year number captures lifetime exposure to risk factors in a way the 10-year window cannot.

This addition reflects a meaningful shift in how preventive cardiology thinks about young adults: a low 10-year score in your thirties does not mean low lifetime risk. The 30-year estimate makes that visible in the conversation.

2. The Age Range Now Starts at 30

The PCE were validated for adults aged 40 to 79. PREVENT-ASCVD is validated from 30 to 79. Combined with the 30-year projection, this lets clinicians have evidence-grounded prevention conversations with younger adults using the same tool used at older ages — rather than waiting until 40 to estimate risk at all.

3. The Inputs Are Broader and More Modern

The PCE used age, sex, race (specifically a Black/non-Black distinction that drew significant criticism), total cholesterol, HDL cholesterol, systolic blood pressure, blood-pressure medication status, diabetes status, and smoking status.

PREVENT-ASCVD uses age, sex, total cholesterol, HDL, systolic blood pressure, blood-pressure medication status, diabetes status, smoking status, body mass index, and estimated glomerular filtration rate (eGFR). There is also an optional version of the equation that incorporates urine albumin-to-creatinine ratio, hemoglobin A1c, and a social deprivation index when those data are available. The race coefficient is gone; the equation does not require race as an input.

The addition of BMI and eGFR matters because both are independently associated with cardiovascular outcomes, and both reflect the broader cardiovascular-kidney-metabolic syndrome the AHA has been emphasizing in recent statements. Kidney function in particular adds substantial information that the PCE missed.

The New Risk Categories

The 2026 guideline defines four risk strata based on the PREVENT 10-year ASCVD estimate:

• Low risk: less than 3%
• Borderline risk: 3% to less than 5%
• Intermediate risk: 5% to less than 10%
• High risk: 10% or higher

These thresholds are different from the PCE's familiar 5%, 7.5%, and 20% breakpoints. They are calibrated to PREVENT's lower absolute estimates — because PREVENT does not overestimate the way the PCE did, the same person plugged into both calculators will often produce a lower PREVENT number, and the thresholds are set accordingly.

The practical implication: if you previously had a PCE-generated risk score and a clinician quoted a number, the new PREVENT number for the same person may be lower. That is not because your underlying risk changed. It is because the new equation is calibrated to current outcomes data.

What Else the 2026 Guideline Added

Two additions beyond the PREVENT switch deserve attention.

Lifetime Lp(a) measurement. The 2026 guideline recommends measuring lipoprotein(a) — Lp(a) — at least once in adulthood. Lp(a) is a genetically determined particle that, when elevated, independently raises ASCVD risk. It is not affected by lifestyle and not lowered by statins. A single measurement gives you information for life. Roughly 1 in 5 adults has an elevated Lp(a), and most do not know it.

Selective ApoB measurement. Apolipoprotein B (ApoB) reflects the total number of atherogenic particles in the blood, not just the cholesterol they carry. The 2026 guideline recommends ApoB measurement in selected cases — particularly when standard lipid panels are discordant, when triglycerides are elevated, or when a clinician needs a clearer signal of atherogenic particle burden.

How the Inputs Map to Habits You Can Track

The PREVENT-ASCVD inputs are the levers that move your number. Some are not modifiable (age, sex). Some are addressable through clinical management (cholesterol, blood pressure, glucose). And several map directly to lifestyle inputs that the calculators on this site can help you quantify.

• Body mass index. BMI is one of the new PREVENT inputs. Use the BMI calculator to track it over time. For context on BMI's strengths and limitations, see BMI versus body fat percentage. Waist-based measures sometimes track cardiovascular risk better than BMI alone — see belly fat versus BMI and the waist-to-height ratio.
• Energy balance and weight management. The most direct lever on BMI and on metabolic risk markers is sustained energy balance. Start with the TDEE calculator for your daily calorie expenditure, then use the calorie calculator to set a target aligned with your weight goal. The macro calculator structures your protein, carbohydrate, and fat targets within that calorie envelope.
• Diet quality and cardiovascular outcomes. Nutrition does not appear as a direct PREVENT input, but it sits upstream of cholesterol, blood pressure, BMI, and diabetes — five of the inputs that do. The AHA 2026 dietary guidelines walk through the nine evidence-based rules for cardiovascular nutrition. Fiber in particular is associated with lower LDL cholesterol; use the fiber intake calculator to set a daily target.
• Hydration and blood pressure context. Adequate water intake is part of fluid regulation that supports blood pressure stability. The water intake calculator sets a daily target.

The point is not that any one calculator on this site moves your PREVENT score by itself. The point is that the score is a function of inputs you can monitor, and most of those inputs respond to consistent habits over months and years.

What to Do With Your Number

If you have had a PREVENT-ASCVD score calculated by a clinician, here are the questions worth asking.

What is my 30-year score, not just my 10-year score? If you are under 50, the 10-year number can look reassuringly low while the 30-year number tells a different story. The 30-year projection is one of the main reasons the new guideline exists.

Has my Lp(a) been measured? If not, ask. It is a one-time test and the result is informative for life. An elevated Lp(a) does not appear in the PREVENT calculation directly, but it changes the interpretation of any PREVENT score because it independently raises risk.

Which inputs are the largest contributors to my score? Different combinations of inputs produce the same score. Knowing which input is weighted most heavily in your case tells you where the largest possible reduction in risk is.

What changes the score the most over the next decade? Some inputs are mostly fixed (age progresses regardless). Others are responsive to consistent action (BMI, blood pressure, glucose, smoking status). The PREVENT score is most useful when you understand which numbers you can move and which you cannot.

The Bottom Line

The 2026 ACC/AHA dyslipidemia guideline retired a calculator that had been the U.S. standard for over a decade and replaced it with one that produces lower, better-calibrated estimates, extends to younger adults, and adds a 30-year projection. PREVENT-ASCVD is more than a recalibrated PCE — it is a different conversation, especially for adults under 50 whose 10-year risk understates their lifetime exposure.

The inputs that drive PREVENT — cholesterol, blood pressure, BMI, kidney function, glucose, smoking — are mostly the inputs that respond to sustained lifestyle and clinical management. The calculator gives you a number. The calculators on this site help you quantify the daily inputs that, over time, move that number.

This article is for informational purposes only and does not constitute medical advice. Cardiovascular risk assessment is a clinical decision that depends on individual history, family history, lab values, and comorbidities. The PREVENT-ASCVD score is a population-derived estimate, not a personal prediction. Discuss your cardiovascular risk and any decisions about screening, monitoring, or medication with a qualified clinician.